Stock ScreenerStock IdeasZen Ratings + Top AnalystsStocks With a Zen Rating of A + Top Analyst consensus of Strong Buy + Large Upside in Target Price: Sep 7, 2025The 2 best sources of winning stocks is the Zen Ratings and our analysis of Top Analysts from Wall Street. Now we have combined them together in a best of both worlds approach to find stocks with the best upside potential.
Stock ScreenerStock IdeasZen Ratings + Top Analysts
Zen Rating: A
Upside/Downside: Large Upside
Top Analysts Consensus: Strong Buy
| Ticker | Company | Zen Rating | Financials | Market Cap | ROE | ROA | ROCE | ROIC | D/E | Current Ratio | Gross Margin | Profit Margin | Operating Margin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | A | B | $688.27B | 88.40% | 16.00% | 27.24% | 22.10% | 4.52 | 1.28 | 82.60% | 25.90% | 31.66% |
| RYAAY | RYANAIR HOLDINGS PLC | A | B | $32.19B | 22.00% | 9.30% | 19.79% | 21.60% | 1.49 | 0.74 | 38.70% | 11.60% | 13.27% |
| WIX | WIXCOM LTD | A | A | $8.56B | -117.80% | 9.00% | 34.65% | 22.70% | -17.96 | 0.81 | 68.40% | 8.90% | 7.68% |
| BGC | BGC GROUP INC | A | C | $4.71B | 16.70% | 3.40% | N/A | 7.20% | 4.07 | N/A | 100.00% | 5.90% | 12.24% |
| IHS | IHS HOLDING LTD | A | B | $2.44B | -28.60% | 2.50% | 23.79% | 15.20% | -16.94 | 1.54 | 50.70% | 6.40% | 52.89% |
| DBD | DIEBOLD NIXDORF INC | A | C | $2.19B | -1.30% | -0.30% | 5.74% | 8.20% | 2.40 | 1.36 | 24.60% | -0.40% | 3.85% |
| FIVN | FIVE9 INC | A | C | $2.06B | 1.40% | 0.40% | 1.49% | 1.20% | 1.38 | 4.44 | 54.90% | 0.80% | 2.02% |
| ARDT | ARDENT HEALTH PARTNERS INC | A | B | $1.88B | 22.30% | 5.20% | 9.43% | 8.10% | 2.70 | 2.13 | 18.30% | 4.10% | 6.31% |
| NTCT | NETSCOUT SYSTEMS INC | A | C | $1.77B | -24.60% | -17.20% | -20.16% | -354.50% | 0.40 | 1.75 | 78.30% | -44.60% | -43.59% |
| BCRX | BIOCRYST PHARMACEUTICALS INC | A | B | $1.74B | N/A | -7.40% | 22.20% | 6.00% | -2.08 | 2.25 | 97.00% | -6.40% | 11.15% |
| AVDL | AVADEL PHARMACEUTICALS PLC | A | B | $1.53B | -3.70% | -1.70% | 3.28% | 4.70% | 1.06 | 2.79 | 89.60% | -1.30% | 1.93% |
| GBX | GREENBRIER COMPANIES INC | A | C | $1.46B | 15.90% | 5.30% | N/A | 7.80% | 1.78 | N/A | 18.50% | 6.50% | 11.86% |
| DCO | DUCOMMUN INC | A | B | $1.35B | 5.20% | 3.10% | 5.88% | 7.00% | 0.63 | 3.34 | 25.60% | 4.50% | 7.11% |
| LMB | LIMBACH HOLDINGS INC | A | B | $1.25B | 22.50% | 10.40% | 20.57% | 32.10% | 1.01 | 1.69 | 28.30% | 6.40% | 8.17% |
| EVER | EVERQUOTE INC | A | A | $859.51M | 32.50% | 21.50% | 28.30% | 456.60% | 0.42 | 3.03 | 96.60% | 7.60% | 7.92% |
| NRDS | NERDWALLET INC | A | B | $795.79M | 8.20% | 6.70% | 0.55% | 1.50% | 0.28 | 2.68 | 90.80% | 4.00% | 0.29% |
| AKBA | AKEBIA THERAPEUTICS INC | A | C | $777.40M | N/A | -18.90% | -9.98% | -30.20% | 11.62 | 2.23 | 68.00% | -24.50% | -11.82% |
| TBPH | THERAVANCE BIOPHARMA INC | A | A | $702.54M | 6.90% | 3.50% | 11.49% | 15.90% | 0.90 | 6.71 | 100.00% | 16.90% | 55.25% |
| KMDA | KAMADA LTD | A | C | $410.59M | 7.40% | 5.20% | 6.05% | 15.50% | 0.42 | 4.00 | 43.60% | 11.20% | 11.51% |
| ELMD | ELECTROMED INC | A | A | $204.30M | 17.50% | 14.50% | 23.73% | 37.60% | 0.25 | 4.31 | 78.10% | 11.80% | 16.07% |
Upgrade to Premium to View More
Use the proven Zen Ratings quant model to find stocks with high potential to beat the market. Stocks Zen-Rated "A" have beaten the market by +32.52% annually. Learn More
Already have access to Premium? Sign In
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.